Abstract 936P
Background
Advanced HNSCC patients with platinum-refractory disease have limited treatment options and poor outcomes, especially in resource-constrained settings. Triple metronomic therapy, a low-dose continuous chemotherapeutic strategy, has shown promise in phase 2 trials but requires further validation. We aimed to evaluate triple OMCT's efficacy in improving overall survival (OS) compared to physician-choice chemotherapy (PCC).
Methods
In this phase 3 open-label study, 214 advanced HNSCC patients previously treated with platinum-based chemotherapy (October 2021-August 2022) were randomized 1:1 to receive triple OMCT (Arm A) with Methotrexate 9 mg/m2 PO weekly, Celecoxib 200 mg twice daily and erlotinib 150 mg daily, or PCC (Arm B), stratified by age and performance status. Primary endpoint was OS, with secondary endpoints including progression-free survival (PFS), Quality of Life (QoL) assessments, and safety. OS and PFS were analyzed using Kaplan-Meier and log-rank tests, with hazard ratios estimated by Cox proportional hazard models. QoL was assessed using EORTC QLQ-C30.
Results
Table: 936P
Baseline characteristics of the patients
Characteristics | Arm A (Triple OMCT) n (%) | Arm B (Physician Choice) n (%) | p-value (Chi-square) |
Age (in years) <60 60 or more | 86 (80.4) 21 (19.6) | 85 (79.4) 22 (20.6) | 0.865 |
Sex Female Male | 6 (5.6) 101 (94.4) | 4 (3.7) 103 (96.3) | 0.517 |
Baseline Hemoglobin level (gm/dL) ≤ 12 > 12 | 68 (63.6) 39 (36.4) | 78 (72.9) 29 (27.1) | 0.142 |
Comorbidities Yes No | 7 (6.5) 100 (93.5) | 16 (15.0) 91 (85.0) | 0.077 |
ECOG Performace Status 1 2 | 68 (63.6) 39 (36.4) | 62 (57.9) 45 (42.1) | 0.401 |
Site of Tumor Oral Cavity Others | 70 (65.4) 37 (34.6) | 71 (66.4) 36 (33.6) | 0.885 |
Most patients had ECOG PS 1 (60.7%) and tumor site in the oral cavity (65.9%). With a median follow-up of 11 months, the median OS was 9 months in Arm A and 5 months in Arm B (HR, 0.63; 95% CI, 0.47–0.83; p=0.00011). Median PFS was 4 months in Arm A and 2 months in Arm B (HR, 0.67; 95% CI, 0.52–0.87; p<0.0001). Multivariate analysis identified age, hemoglobin level, and comorbidity as significant OS prognostic factors. No significant QoL score differences were observed. Triple OMCT showed fewer grade 3 or higher adverse events than PCC (28.0% vs 39.3%, p=0.03).
Conclusions
Triple OMCT is an effective, safe treatment for advanced HNSCC patients previously treated with platinum-based chemotherapy, offering improved OS and tolerable side effects compared to physician-choice chemotherapy.
Clinical trial identification
Clinical Trial Registry-India CTRI/2021/09/036296.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Indian Cooperative Oncology Network (ICON) Trust.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
878P - INHBA is overexpressed in HPV-negative oropharyngeal squamous cell carcinoma and contributes to an aggressive phenotype
Presenter: Simon Laban
Session: Poster session 12
880P - ctHPV16-DNA in Liquid Biopsy: A promising biomarker to monitor disease status in patients with HPV-positive oropharyngeal squamous cell carcinoma
Presenter: Nora Würdemann
Session: Poster session 12
881P - SOTO study: Prospective study to correlate the treatment sensitivity of patient-derived organoids (PDOs) with treatment outcomes in head and neck cancer patients
Presenter: Ifigenia Vasiliadou
Session: Poster session 12
882P - Claudin-1 (CLDN1) expression in head and neck squamous cell carcinoma (HNSCC) patients
Presenter: Stefano Cavalieri
Session: Poster session 12
884P - Prognostic value and immune characteristics of LGALS1 in head and neck squamous cell carcinoma
Presenter: Yanfei Min
Session: Poster session 12
885P - Clinical significance of folate receptor-positive circulating tumor cells detected by ligand-targeted polymerase chain reaction in nasopharyngeal carcinoma
Presenter: Dingyi Wang
Session: Poster session 12
887P - Antitumor activity of the radioenhancer NBTXR3 on injected lesions to estimate overall survival: Exploratory analyses from a phase I in cisplatin-ineligible locally advanced HNSCC patients
Presenter: Christophe Le Tourneau
Session: Poster session 12
888P - Phase I study of olaparib combined with loco-regional radiotherapy in patients with head and neck squamous cell carcinoma
Presenter: Marcel Verheij
Session: Poster session 12